Aptevo Therapeutics (APVO) – Company Press Releases
-
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
-
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
-
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
-
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
-
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
-
Aptevo to Present at Bio-Europe Conference
-
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
-
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
-
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
-
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
-
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
-
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
-
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
-
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
-
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
-
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
-
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
-
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
-
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
-
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
-
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
-
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
-
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
-
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
-
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
-
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
-
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
-
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
-
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
-
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
-
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
-
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
-
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
-
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
-
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
-
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
-
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
-
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
-
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
-
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
-
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
-
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
-
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
-
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
-
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
-
Aptevo Confirms Receipt of Nominations and Proposal Notice
-
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
-
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
-
Aptevo Confirms Receipt of Unsolicited Indication of Interest
-
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Back to APVO Stock Lookup